Skip to main content
. 2017 Oct 24;25:112–121. doi: 10.1016/j.ebiom.2017.10.018

Table 1.

Demographic and clinical characteristics of the study population.

No. patients
Number with stable sputum conversion on solid and liquid media
(% of total) (% of category)
Characteristic At 8 weeks At 12 weeks At 16 weeks
All subjects 319 (100%) 209 (66%) 264 (83%) 316 (99.1%)
Gender
 Female 107 (34%) 86 (80%) 93 (87%) 105 (98.1%)
 Male 212 (66%) 123 (58%) 171 (81%) 211 (99.5%)
Age
 0–20 17 (5%) 13 (76%) 16 (94%) 17 (100.0%)
 21–40 203 (64%) 128 (63%) 169 (83%) 203 (100.0%)
 41–60 80 (25%) 54 (68%) 63 (79%) 78 (97.5%)
 61 19 (6%) 14 (74%) 16 (84%) 18 (94.7%)
Body mass index
 BMI ≤ 18.5 97 (30%) 56 (58%) 80 (82%) 95 (97.9%)
 BMI > 18.5 222 (70%) 153 (69%) 184 (83%) 221 (99.5%)
Location
 N. America 109 (34%) 85 (78%) 99 (91%) 107 (98.2%)
 Spain 24 (8%) 17 (71%) 19 (79%) 24 (100.0%)
 S. Africa 64 (20%) 44 (69%) 54 (84%) 64 (100.0%)
 Uganda 122 (38%) 63 (52%) 92 (75%) 121 (99.2%)
HIV status
 Negative 284 (89%) 189 (67%) 235 (83%) 282 (99.3%)
 Positive 35 (11%) 20 (57%) 29 (83%) 34 (97.1%)
Baseline smear
 Low 114 (36%) 91 (80%) 102 (89%) 114 (100.0%)
 High 205 (64%) 118 (58%) 162 (79%) 202 (98.5%)
Baseline chest x-Ray
 No cavity 115 (36%) 84 (73%) 98 (85%) 115 (100.0%)
 Cavity ≤ 4 cm 80 (25%) 54 (68%) 70 (88%) 79 (98.8%)
 Cavity > 4 cm 124 (39%) 71 (57%) 96 (77%) 122 (98.4%)
Baseline MGIT960
 TTD < = 5 days 82 (26%) 45 (55%) 64 (78%) 79 (96.3%)
 TTD > 5 days 237 (74%) 164 (69%) 200 (84%) 237 (100.0%)
Study arm
 Rifampin 151 (47%) 93 (62%) 124 (82%) 151 (100.0%)
 Rifapentine 168 (53%) 116 (69%) 140 (83%) 165 (98.2%)

MGIT960 TTD refers to the time-to-detection for baseline liquid mycobacterium growth indicator tube system (MGIT) 960 cultures. Sputum conversion indicates negative sputum culture on both solid and liquid media at the specified time point.